AEZS - Aeterna Zentaris Inc.
| Previous Close | 1.0500 |
| Open | 1.0300 |
| Bid | 0.9400 x 3100 |
| Ask | 1.0400 x 1400 |
| Day's Range | 1.0000 - 1.0500 |
| 52 Week Range | 0.8100 - 5.5700 |
| Volume | 74,972 |
| Avg. Volume | 146,487 |
| Market Cap | 20.671M |
| Beta (3Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7480 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Zacks
What Makes Aeterna Zentaris (AEZS) a New Buy Stock
Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer
Aeterna Zentaris Inc. (AEZS) (AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective today, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company. Dr. Paulini will continue to be based in Frankfurt, Germany, and his appointment as President and Chief Executive Officer aligns with the Company’s refocus on its operations in Germany.
- Simply Wall St.
Can We See Significant Institutional Ownership On The Aeterna Zentaris Inc. (TSE:AEZS) Share Register?
Every investor in Aeterna Zentaris Inc. (TSE:AEZS) should be aware of the most powerful shareholder groups...
- GlobeNewswire
Aeterna Zentaris Announces Closing of Approximately $5.0 Million Registered Direct Offering
Aeterna Zentaris Inc. (AEZS) (AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced the closing of its previously announced offering whereby the Company entered into a securities purchase agreement with institutional investors in the United States to purchase approximately $5.0 Million (before placement agent’s fees and expenses) of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement (together, the “Offering”). The combined purchase price for one common share and one warrant was $1.50.
- GlobeNewswire
Aeterna Zentaris Announces Pricing of Approximately $5.0 Million Registered Direct Offering
Aeterna Zentaris Inc.Aeterna Zentaris Inc. (AEZS) (AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced today that it has entered into a securities purchase agreement with institutional investors in the United States to purchase approximately $5.0 million of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined purchase price for one common share and one warrant will be $1.50. Under the terms of the securities purchase agreement, Aeterna has agreed to sell 3,325,000 shares of its common shares.
- GlobeNewswire
Aeterna Zentaris Announces Director Change
CHARLESTON, S.C., Aug. 20, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that Jonathan Pollack has resigned as a director of the Company for personal.
- Zacks
Aeterna Zentaris (AEZS) Beats Q2 Earnings Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 107.14% and -3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results
CHARLESTON, S.C., Aug. 13, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the second quarter ended June 30,.
- Zacks
Will Aeterna Zentaris (AEZS) Report Negative Q2 Earnings? What You Should Know
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Options Traders Expect Huge Moves in Aeterna Zentaris (AEZS) Stock
Aeterna Zentaris (AEZS) needs investors to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire
Aeterna Zentaris Provides Corporate Update
Aeterna Zentaris Inc. (AEZS) (AEZS) today announced that it is reducing the size of its German workforce and operations to more closely reflect the Company's ongoing commercial activities in Frankfurt. The Company is also providing an update on the previously disclosed securities class action lawsuit pending in the U.S. District Court for the District of New Jersey, brought on behalf of shareholders of the Company. The lawsuit alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between August 30, 2011 and November 6, 2014 regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company's New Drug Application for the product by the FDA.
- GlobeNewswire
Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
CHARLESTON, S.C., May 08, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) announced today at its annual and special shareholders’ meeting held on May 8, 2019, that the.
- Zacks
Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Aeterna Zentaris: 1Q Earnings Snapshot
The Summerville, South Carolina-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs and research and development costs, came to 14 cents per share. The drug ...
- GlobeNewswire
Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results
CHARLESTON, S.C., May 07, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the first quarter ended March 31,.
- Zacks
What's in the Cards for AEterna (AEZS) This Earnings Season?
AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.
- Zacks
Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Associated Press
Aeterna Zentaris: 4Q Earnings Snapshot
The Summerville, South Carolina-based company said it had a loss of 31 cents per share. The drug developer posted revenue of $1.4 million in the period. For the year, the company reported net income of ...
- GlobeNewswire
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
Aeterna Zentaris Inc. (AEZS) (AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. The increase in total revenue in 2018 relates to license fees, royalty income and product sales associated with executing the License and Assignment Agreement for Macrilen™ (macimorelin) in January 2018.
- GlobeNewswire
Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
Aeterna Zentaris Inc. (AEZS) (AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada.
- Zacks
Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade
Aeterna Zentaris (AEZS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Benzinga
The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...
- GlobeNewswire
Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor
Aeterna Zentaris Inc. (AEZS) (AEZS) announced today that its board of directors has formed a special committee of independent directors (the “Special Committee”) to review strategic options available to Aeterna Zentaris. The Special Committee has approved the engagement by the Company of Torreya, a global investment bank specializing in life sciences, as its financial advisor. Torreya is working with management to assist the Special Committee and the board of directors in considering a wide range of transactions (including opportunities for the license of macimorelin outside of the United States and Canada, other monetization transactions relating to macimorelin or the potential sale of the company) which may create value for the company, its shareholders and other stakeholders.
- Zacks
What's in the Cards for Aeterna (AEZS) This Earnings Season?
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
- Zacks
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
